Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab

<p><strong>Objectives</strong></p><p>Treat to target recommendations for PsA state that the target of treatment should be remission or, at the very least, low disease activity. Different clinical indexes have been proposed to define these disease states including the mi...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Coates, L, Rahman, P, Psaradellis, E, Rampakakis, E, Osborne, B, Lehman, A, Nantel, F
Μορφή:	Journal article
Έκδοση:	Oxford University Press 2018

Παρόμοια τεκμήρια

Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry
ανά: Emmanouil Rampakakis, κ.ά.
Έκδοση: (2020-08-01)

Golimumab for the treatment of psoriatic arthritis
ανά: H Yang, κ.ά.
Έκδοση: (2011-05-01)

Golimumab in the treatment of psoriatic arthritis: efficacy and safety
ανά: Tatiana Viktorovna Korotaeva, κ.ά.
Έκδοση: (2015-09-01)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
ανά: Proton Rahman, κ.ά.
Έκδοση: (2020-09-01)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
ανά: M. Rossini, κ.ά.
Έκδοση: (2015-03-01)

Sustained very low disease activity and remission in psoriatic arthritis patients
ανά: Lubrano, E, κ.ά.
Έκδοση: (2019)

Considerations for the definition of remission criteria in psoriatic arthritis
ανά: Mease, P, κ.ά.
Έκδοση: (2017)

Golimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations
ανά: Sydney Moore McIntosh, κ.ά.
Έκδοση: (2023-07-01)

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis
ανά: Melissa A Michelon, κ.ά.
Έκδοση: (2010-05-01)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
ανά: Ennio Lubrano, κ.ά.
Έκδοση: (2019-08-01)

Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry
ανά: Proton Rahman, κ.ά.
Έκδοση: (2020-11-01)

Remission in psoriatic arthritis—where are we now?
ανά: Coates, L, κ.ά.
Έκδοση: (2017)

What should be the primary target of "treat to target" in psoriatic arthritis?
ανά: Coates, LC, κ.ά.
Έκδοση: (2018)

Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort
ανά: van Mens, L, κ.ά.
Έκδοση: (2017)

Comparison of different remission and low disease definitions in patients with psoriatic arthritis and evaluation of their prognostic value
ανά: Coates, LC, κ.ά.
Έκδοση: (2018)

Novel concepts in psoriatic arthritis management: Can we treat to target?
ανά: Tucker, L, κ.ά.
Έκδοση: (2018)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
ανά: Coates, L, κ.ά.
Έκδοση: (2022)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
ανά: M. Elaine Husni, κ.ά.
Έκδοση: (2022-03-01)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
ανά: Coates, L, κ.ά.
Έκδοση: (2018)

Mixed methods study of clinicians’ perspectives on barriers to implementation of treat to target in psoriatic arthritis
ανά: Dures, E, κ.ά.
Έκδοση: (2020)

THE EFFECT OF GOLIMUMAB ON ARTERIAL STIFFNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS
ανά: L. A. Knyazeva, κ.ά.
Έκδοση: (2018-03-01)

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study
ανά: Philip Mease, κ.ά.
Έκδοση: (2020-11-01)

Using etanercept to maintain remission of psoriatic arthritis during pregnancy
ανά: Ibrahim A Al-Homood, κ.ά.
Έκδοση: (2014-01-01)

2-years outcomes of the treat-to-target strategy in early psoriatic arthritis
ανά: E. Yu. Loginova, κ.ά.
Έκδοση: (2022-11-01)

GOLIMUMAB SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
ανά: Wordsworth, P, κ.ά.
Έκδοση: (2009)

Difficult-to-treat psoriatic arthritis. Data from the All-Russian registry of patients with psoriatic arthritis
ανά: E. Yu. Loginova, κ.ά.
Έκδοση: (2024-10-01)

Use of a multidimensional RAPID3 questionnaire to assess the achievement of remission and minimal disease activity in patients with early psoriatic arthritis treated according to Treat-to-target strategy
ανά: E. Yu. Loginova, κ.ά.
Έκδοση: (2019-01-01)

Psoriatic arthritis: prospects for the future
ανά: Hackett, S, κ.ά.
Έκδοση: (2022)

Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
ανά: Taylor, P, κ.ά.
Έκδοση: (2011)

Measuring outcomes in psoriatic arthritis
ανά: Ogdie, A, κ.ά.
Έκδοση: (2020)

Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study
ανά: Leung, Y-Y, κ.ά.
Έκδοση: (2023)

Psoriatic arthritis
ανά: FitzGerald, O, κ.ά.
Έκδοση: (2021)

Psoriatic arthritis: prospects for the future
ανά: Simon Hackett, κ.ά.
Έκδοση: (2022-03-01)

Golimumab therapy-induced indicators of X-ray inflammation progression and magnitude according to magnetic resonance imaging evidence in patients with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis
ανά: Aleksandr Viktorovich Smirnov
Έκδοση: (2013-06-01)

The road to personalised medicine in psoriatic arthritis
ανά: White, JPE, κ.ά.
Έκδοση: (2021)

Psoriatic arthritis: An up to date overview
ανά: Simon Hackett, κ.ά.
Έκδοση: (2020-01-01)

Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity
ανά: Ye, W, κ.ά.
Έκδοση: (2018)

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries
ανά: Gorlier, C, κ.ά.
Έκδοση: (2018)

Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
ανά: Sofia Lanz, κ.ά.
Έκδοση: (2021-08-01)

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer
ανά: Ananaya Datta-Mitra, κ.ά.
Έκδοση: (2014-01-01)